Quick Answer
Design Therapeutics, Inc. reported R&D Expense of $59.13 million for fiscal year 2025.
Design Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $59.13M | +33.3% |
| 2024 | $44.35M | -22.3% |
| 2023 | $57.06M | +17.4% |
| 2022 | $48.61M | +96.2% |
| 2021 | $24.78M | +308.9% |
| 2020 | $6.06M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $14.59M | +22.8% | -7.3% |
| June 30, 2025 | $15.74M | +49.7% | +2.3% |
| March 31, 2025 | $15.38M | +56.9% | +29.5% |
| September 30, 2024 | $11.88M | -10.4% | +12.9% |
| June 30, 2024 | $10.52M | -38.4% | +7.3% |
| March 31, 2024 | $9.80M | -37.7% | -26.1% |
| September 30, 2023 | $13.26M | -7.3% | -22.3% |
| June 30, 2023 | $17.06M | +51.1% | +8.5% |
- Design Therapeutics, Inc. showed an increase of +33.3% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Design Therapeutics, Inc.’s r&d expense has grown by 875.7% (from $6.06 million to $59.13 million).
- The most recent figure is from Design Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: